Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.
Needham analyst Gil Blum reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.
NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.59) by...
HC Wainwright & Co. analyst Emily Bodnar maintains NextCure (NASDAQ:NXTC) with a Buy and raises the price target from $5...
Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.
Financial Results for Full Year Ended December 31, 2023Cash, cash equivalents, and marketable securities as of December 31, 202...
